My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
February 2009
Volume 19 Issue 2
Policy and Advocacy
HIVMA Urges Medicare to Cover Treatment of Facial Lipodystrophy

Reconstructive treatments for facial lipodystrophy syndrome (FLS) are reasonable, medically necessary, and appropriate for patients with HIV/AIDS who have or are undergoing antiretroviral therapy (ART), HIVMA said in a comment letter to the Centers for Medicare and Medicaid Services (CMS). CMS recently opened its national coverage determination process on Medicare coverage for the treatment. CMS plans to issue a proposed decision by July 2009 and a final decision by October 2009.
How useful is this article?

< Previous Article | Next Article >

Post a comment

Your name:

Your comment:


Top Stories
Candidiasis Guidelines Updated
IDSA Journal Club
From the President
Vaccine Science Prevails
Patient Care and Science
EIN Considers Alternatives to Acyclovir During Shortage
Updated Rotavirus Recommendations Include New Vaccine
ACIP Changes Recommendations for Anthrax, Hepatitis A Vaccines
Drug Approvals, Recalls, Adverse Events Update
Practice Management
CMS Sending Clinicians Reports on their Medicare Costs
How to Put Health IT to Work in Your Practice
Policy and Advocacy
Federal HAI Prevention Plan is “Important First Step”
Stimulus Funding May Go Toward ID Research, HIV/AIDS Prevention
HIVMA Urges Medicare to Cover Treatment of Facial Lipodystrophy
Advocacy Update: IDSA Expresses Concern About State Lyme Disease Bills
Education and Training
SHEA Offers California Epidemiology Course
You and Your Colleagues
Welcome New IDSA Members!

IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'idsa@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.